Gilead expanded its Tempus partnership, granting the drugmaker broader access to Tempus’s multimodal real-world cancer dataset library and its AI platform. Tempus said the multi-year collaboration includes additional data across indications beyond de-identified records already used to support trial design and biomarker-defined strategies. The expanded deal also positions Tempus’s Lens analytics stack—built on a cloud-based workflow integrating tumor and matched normal DNA/RNA and H&E slide data—as a layer for cohort discovery and trial simulation. Tempus added that Lens includes a large language model to support researchers querying datasets and retrieving detailed information about datapoints. For Gilead, the move signals a continued shift toward data-driven oncology development cycles, where real-world evidence is used to de-risk biomarker targeting and accelerate decision-making across programs.